Garmin Ltd. (NASDAQ:GRMN) [Trend Analysis] moved up reacts as active mover, shares an increase 7.33% to traded at $54.15 and the percentage gap between open changing to regular change was 7.63%. Garmin Ltd. (GRMN) declared fourth-quarter profit of $136.6 million. The Schaffhausen, Switzerland-based company said it had profit of 72 cents per share. Earnings, adjusted for non-recurring costs, were 73 cents per share. The results exceeded Wall Street expectations.
The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 58 cents per share. The maker of personal navigation devices posted revenue of $860.8 million in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $796.4 million. For the year, the company declared profit of $510.8 million, or $2.70 per share. Revenue was declared as $3.02 billion. Garmin expects full-year earnings to be $2.65 per share, with revenue expected to be $3.02 billion.
The firm’s current ratio calculated as 2.40 for the most recent quarter. The firm past twelve months price to sales ratio was 3.48 and price to cash ratio remained 9.18. As far as the returns are concern, the return on equity was recorded as 15.20% and return on investment was 13.10% while its return on asset stayed at 11.20%. The firm has total debt to equity ratio measured as 0.00.
Bristol-Myers Squibb Company (NYSE:BMY) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.04% to close at $55.35 with the total traded volume of 21.28 Million shares. Bristol-Myers Squibb Company (BMY) reported that it has agreed to sell $1.5 billion of senior unsecured notes: $750 million in aggregate principal amount of 1.600% notes due 2019 and $750 million in aggregate principal amount of 3.250% notes due 2027, in an underwritten public offering. Goldman, Sachs & Co., Morgan Stanley & Co. LLC, Merrill Lynch, Pierce, Fenner& Smith Incorporated, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering.
Bristol-Myers Squibb intends to use the proceeds from the offering to fund its share repurchase program and for general corporate purposes. The firm has institutional ownership of 71.70%, while insider ownership included 0.10%. Its price to sales ratio ended at 4.73. BMY attains analyst recommendation of 2.40 with week’s performance of 3.05%.